Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 394Neoplasms 351Carcinoma, Non-Small-Cell Lung 303Prostatic Neoplasms 255Colorectal Neoplasms 226Lung Neoplasms 197Multiple Myeloma 162Ovarian Neoplasms 152Neoplasm Metastasis 146Pancreatic Neoplasms 142Leukemia, Myeloid, Acute 135Melanoma 117Squamous Cell Carcinoma of Head and Neck 98Recurrence 96Carcinoma, Renal Cell 94Lymphoma 92Endometrial Neoplasms 92Brain Neoplasms 92Lymphoma, Non-Hodgkin 91Stomach Neoplasms 88Carcinoma, Hepatocellular 87Precursor Cell Lymphoblastic Leukemia-Lymphoma 85Head and Neck Neoplasms 80Glioblastoma 79Uterine Cervical Neoplasms 78Hematologic Neoplasms 76Urinary Bladder Neoplasms 74Leukemia, Lymphocytic, Chronic, B-Cell 74Glioma 74Triple Negative Breast Neoplasms 69

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Malignant Peripheral Nerve Sheath Tumors × 30 days × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡